Integrated physiology and systems biology of PPARα

Sander Kersten*

ABSTRACT

The Peroxisome Proliferator Activated Receptor alpha (PPARα) is a transcription factor that plays a major role in metabolic regulation. This review addresses the functional role of PPARα in intermediary metabolism and provides a detailed overview of metabolic genes targeted by PPARα, with a focus on liver. A distinction is made between the impact of PPARα on metabolism upon physiological, pharmacological, and nutritional activation. Low and high throughput gene expression analyses have allowed the creation of a comprehensive map illustrating the role of PPARα as master regulator of lipid metabolism via regulation of numerous genes. The map puts PPARα at the center of a regulatory hub impacting fatty acid uptake, fatty acid activation, intracellular fatty acid binding, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis, triglyceride turnover, lipid droplet biology, gluconeogenesis, and bile synthesis/secretion. In addition, PPARα governs the expression of several secreted proteins that exert local and endocrine functions.

Keywords PPARα; Liver; Transcriptional networks; Lipid metabolism; Expression profiling; Metabolic homeostasis; Systems biology

1. INTRODUCTION

PPARα was the first member to be cloned of a small subfamily of nuclear receptors called Peroxisome Proliferators Activated Receptors [1]. The other members of this subfamily are PPARδ, also referred to as PPARβ, and PPARγ [2]. Peroxisome proliferators encompass a diverse set of synthetic compounds that cause peroxisome proliferation and liver cancer in mice. Contradicting their name, PPARδ and PPARγ are not activated by peroxisome proliferators, in contrast to PPARα. The PPAR subfamily is part of the larger family of nuclear receptors that also includes receptors for fat soluble vitamins, steroid hormones, and sterols [3]. Nuclear receptors share a conserved modular structure consisting of a N-terminal domain involved in transcriptional activation, a DNA-binding domain containing a zinc-twist structure, a short hinge region, and a relatively spacious ligand binding domain, which accommodates the lipophilic ligands and also harbors a transcriptional activation function at the far C-terminus [4].

PPARs bind to DNA as a heterodimer with the Retinoid X Receptor RXR, and together they recognize specific DNA sequences in and around target genes referred to as PPAR response elements [5]. These PPAR response elements or PPREs consist of a direct repeat of the consensus hexanucleotide AGGTCA spaced by a single nucleotide. Agonist ligands for PPARs may promote the physical association of the PPAR—RXR heterodimer to DNA, but substantial binding of PPARs to DNA already occurs in the basal state [6]. In contrast to other nuclear receptor—RXR pairs, PPAR—RXR heterodimers are “permissive”, which means that they can be activated by either an RXR-selective ligand (“rexinoid”) or a PPAR ligand [7–9]. Binding of ligand leads to the dissociation of co-repressor proteins and the association of co-activator proteins, which can recruit or have intrinsic histone deacetylase and histone acetyltransferase activity, respectively, necessary for the assembly of the transcription initiation complex [10]. Readers are referred to another review for more detailed information on co-activators in PPAR-dependent gene regulation [11]. In addition to via direct binding to PPREs, PPARs and PPAR ligands also regulate gene expression by altering the activity of other transcription factors via direct protein—protein interactions. This action of PPARs generally inhibits the function of the other transcription factor and is referred to as transrepression. Transrepression predominantly accounts for the inhibitory effect of PPARs on inflammation related genes [12].

The most abundant natural ligands for PPARs encompass different types of (dietary) fatty acids and fatty-acid derived compounds, including various eicosanoids [13]. In addition, numerous dietary plant bioactive compounds have been suggested to serve as PPAR agonist, although the in vivo relevance of PPAR activation by these compounds remains uncertain. Finally, PPARs are the molecular target of different classes of drugs used in the treatment of diabetes and dyslipidemia. All three PPARs are expressed in a variety of tissues [14,15]. Expression of PPARγ is most restrictive, showing high expression in white and brown adipocytes, macrophages and colonocytes, with lower expression in skeletal muscle and many other tissues. PPARα is expressed in virtually all tissues and cell types examined, while expression of PPARγ is highest in liver and brown adipose tissue, followed by small intestine, heart and kidney (http://biogps.org). This review will concentrate on PPARα.

Since its discovery, PPARα has evolved from an intracellular receptor for synthetic peroxisome proliferators into one of the key transcriptional regulators of intermediary metabolism and an intermediate in the pathogenesis of numerous diseases [16]. Although most of our
knowledge on PPARα is connected to its presence in the liver, studies on PPARα in other tissues, including heart [17,18], and small intestine [19] have indicated that the role of PPARα in metabolic homeostasis is relatively well conserved between different cell types. The first part of this review addresses the role of PPARα in intermediary metabolism in liver. A distinction is made between the metabolic function of PPARα upon physiological, pharmacological, and nutritional PPARα activation. As a transcription factor, PPARα governs biological processes by altering the expression of numerous target genes. Accordingly, the functional role of PPARα is directly related to the biological function of its target genes. In the second part of the review, a comprehensive overview is provided of metabolic genes targeted by PPARα, organized into specific metabolic pathways.

2. REGULATION OF INTERMEDIARY METABOLISM BY PPARα

2.1. Physiological PPARα activation during fasting

2.1.1. Regulation of the adaptive response to fasting by PPARα

Throughout our ancestral history, fasting and starvation were common occurrences that posed a major threat to the survival of the human species. As a consequence, humans have developed an adaptive response mechanism to fasting that relies on two main pillars: 1) generation of a strong hunger sensation that triggers food-seeking behavior and 2) a shift in fuel utilization to exploit the abundant triglyceride stores in the adipose depot. A key event during fasting is activation of adipose tissue lipolysis, contributing to a gradual shift in whole-body fuel utilization from glucose and fatty acids in the fed state to almost exclusively fatty acids after a day of fasting [20]. The shift in fuel utilization is governed by changes in the production of the metabolic hormones insulin and glucagon, as well as by altered secretion of several gut- and adipose-tissue derived hormones. Within this complex network of metabolic adjustments, the liver plays a key role through its exclusive ability to synthesize glucose and catalyze the formation of ketone bodies [20]. Ample provision of glucose and ketone bodies is necessary to meet the needs of the metabolically active brain, which unlike other tissues and organs is unable to utilize fatty acids as fuel. Research in the past two decades has shown that PPARα is a master regulator of hepatic nutrient metabolism during fasting [21–23]. Specifically, PPARα induces hepatic fatty acid oxidation and ketogenesis and regulates hepatic glucose production, which are key events in the adaptive response to fasting (Figure 1). Additionally, PPARα governs hepatic amino acid metabolism. Elucidation of the role of PPARα during fasting has benefited immensely from the availability of PPARα−/− mice, which exhibit a striking fasting-induced phenotype [21–23].

2.1.2. Regulation of hepatic lipid homeostasis during fasting by PPARα

As indicated above, a crucial event during fasting is activation of adipose tissue lipolysis, resulting in elevated circulating levels of glycerol and free fatty acids (FFA) and elevated flux of fatty acids into many tissues including liver. Increased hepatic uptake of fatty acids during fasting is associated with activation of a number of pathways, most prominently the activation of hepatic fatty acid oxidation and concomitant production of ketone bodies (Figure 2A). Metabolic data have unequivocally demonstrated the crucial role of PPARα in stimulation of hepatic fatty acid oxidation and ketogenesis [21–25]. Indeed, the increase in plasma ketone body levels during fasting is largely abolished in fasted mice lacking PPARα [26] (Figure 2B, Table 1), which is caused by blunted fasting-induced upregulation of numerous PPARα target genes involved in fatty acid oxidation (e.g. Cpt1a, Cpt2, Acadvl, Hadha) and ketogenesis (Hmgcs2, Hmgcl, Acat1). Furthermore, plasma levels of long chain acyl-carnitines are increased in fasted PPARα−/− mice, whereas plasma levels of medium and short chain acyl-carnitines and free carnitine are decreased, reflecting impaired fatty acid oxidation (Table 1) [21,27]. Decreased rates of hepatic fatty acid oxidation and

---

**Figure 1**: Overall role of PPARα in the adaptive response to fasting. Fasting is associated with activation of adipose tissue lipolysis, leading to the release of free fatty acids and glycerol into the circulation. Free fatty acids taken up by the liver are partially oxidized and converted into ketone bodies, or completely oxidized to CO2. Glycerol is converted into glucose, as are amino acids coming from skeletal muscle. The processes induced by PPARα are indicated by green arrows. The processes suppressed by PPARα are indicated by red arrow. TG = triglycerides, FA = fatty acids, KB = ketone bodies, AA = amino acids.
Ketogenesis were confirmed in primary hepatocytes of PPARα−/− mice compared with wildtype mice [28]. Due to a reduced capacity for fatty acid oxidation, a large share of the incoming fatty acids is diverted towards triglyceride synthesis via a pathway that does not seem to be noticeably affected by PPARα deletion. Consequently, liver triglyceride levels are markedly elevated in fasted PPARα−/− mice compared with fasted wildtype mice [21,22,26] (Figure 2, Table 1). In addition, plasma and liver concentrations of FFA are elevated in fasted PPARα−/− mice because of impaired fatty acid oxidation [22,26,29]. For reasons that are unclear, plasma triglyceride levels are elevated in PPARα−/− mice only in the fed but not fasted state [21,26]. An overview of the metabolic changes in plasma and liver of PPARα−/− mice is provided in Table 1. The markedly disturbed response to fasting in PPARα−/− mice thus illustrates the profound importance of PPARα in governing hepatic lipid metabolism during fasting.

2.1.3. Regulation of hepatic glucose homeostasis during fasting by PPARα

Besides leading to dramatic alterations in lipid metabolism, deletion or knock-down of PPARα also causes severe fasting-induced hypoglycemia and reduces intra-hepatic glucose levels, indicating a major impact of PPARα on glucose homeostasis [21–23,29–31]. Several explanations for the hypoglycemia have been put forward. First, hepatic glycogen level are lower in (re)-fed PPARα−/− mice [22,29,31–33], likely leading to reduced glycogen breakdown and glucose release during early fasting. Metabolic changes detected in the liver of PPARα−/− mice are consistent with reduced glucose storage and glucose production by gluconeogenesis (Table 1) [29]. The lower glycogen levels may be due to reduced expression of Gys2, leading to a diminished rate of glycogen formation upon (re) feeding [25,31,32]. Alternatively, it was suggested that impaired fatty acid oxidation and resultant ATP and NADH shortage in livers of PPARα−/− mice may disable gluconeogenesis [22]. However, the stimulatory effect of fatty acid oxidation on gluconeogenesis appears to be minimal [34]. Another potential explanation for the fasting hypoglycemia in PPARα−/− mice is decreased hepatic gluconeogenesis from glycerol, uptake and conversion of which is under direct control of PPARα [24]. However, tracer studies have not supported this notion. One tracer study found that total hepatic glucose production and hepatic glucose production from glycerol were increased in PPARα−/− mice in the fasted state, whereas hepatic glucose production from lactate was reduced [31]. Another study reported that after a short-term fast the gluconeogenic flux in PPARα−/− mice is directed more towards glycogen, leading to a decrease in hepatic glucose output [32]. Despite the ambiguity emerging from tracer studies, the observation that the fasting-induced increase in expression of several genes involved in the gluconeogenic pathway (Pcx, Fbp1, Gpd1, Gyk, Slc16a1), many of which represent PPARα target genes, is abolished in PPARα−/− mice provides strong evidence that gluconeogenesis is directly targeted by PPARα [35]. This notion is further supported by reduced rates of glucose synthesis from lactate/pyruvate in primary hepatocytes from PPARα−/− mice compared to wildtype mice [28]. Other gluconeogenic genes that have been reported to be reduced in PPARα−/− mice include G6pc (glucose 6 phosphatase) and Pck1 (phosphoenolpyruvate carboxykinase) [31,32,36]. However, others have not been able to confirm these findings. Finally, apart from changes in glucose production, there is ample evidence that the fasting hypoglycemia is at least partially caused by elevated peripheral glucose utilization, likely as a result of impaired fatty acid oxidation and a reduced supply of ketone bodies [36,37].

| Intracellular | Increased          | Decreased          |
|---------------|-------------------|--------------------|
| Triglycerides | Short chain acyl-carnitines | Free carnitine |
| Long chain acyl-carnitines | Glucose |
| Free fatty acids | Glycogen |
| Glycogen (fasted state) | Glucose |

| Blood plasma | Increased | Decreased |
|--------------|-----------|-----------|
| Triglycerides (in fed state) | Short chain acyl-carnitines | Free carnitine |
| Long chain acyl-carnitines | Free carnitine |
| Free fatty acids | Ketone bodies |
| Urea | Glucose |
| Arginine | Tyrosine |
| Alanine | Tyrosine |

Table 1: Metabolites changes in PPARα−/− mice.
2.1.4. Regulation of hepatic amino acid metabolism during fasting by PPARα

PPARα not only is the master regulator of hepatic lipid and glucose homeostasis but also has a profound impact on amino acid metabolism. Specifically, PPARα downregulates the expression of numerous enzymes involved in amino acid degradation, transamination and the urea cycle (Got1, Prodh, Glu2, Pah, Sds, Asl, Ass1, Cps1) [35,38]. In agreement with enhanced amino acid degradation and urea synthesis, plasma urea levels are elevated in PPARα−/− mice, whereas plasma levels of several amino acids (arginine, tyrosine, alanine) are reduced [27,38]. These data demonstrate that during fasting PPARα minimizes amino acid degradation and ureagenesis, which together with induction of fatty acid oxidation is part of an adaptive mechanism aimed at relying maximally on stored triglycerides as fuel, as opposed to breaking down valuable muscle tissue and oxidizing amino acids [27]. The molecular mechanisms underlying downregulation of amino acid metabolism by PPARα remain elusive.

2.1.5. Mechanism of activation of PPARα during fasting

Induction of most of the above described genes by fasting is dependent on PPARα, which suggests that PPARα in liver is activated during fasting. Activation of PPARα during fasting is supported by experiments using in vivo PPAR-reporter mice [39]. Since fatty acids are ligands for PPARα [40], and plasma FFA increase during fasting, it has been tempting to attribute the activation of hepatic PPARα during fasting to increased plasma FFA uptake into the liver [22]. However, studies suggest that plasma FFA cannot activate PPARα in liver [41,42]. An alternative mechanism for PPARα activation during fasting is via induction of PPARα mRNA [22]. In line with major regulation at the mRNA level, PPARα mRNA follows a pronounced circadian rhythm that is inversely related to feeding status [43,44]. In addition, circadian transcription of genes encoding acyl-CoA thioesterases may lead to rhythmic changes in the intracellular level of fatty acid ligands [44]. Other potential mechanisms for PPARα activation during fasting include induction of co-activator proteins such as PGC1α [42], and intracellular generation of PPARα ligands via lipolysis of locally stored triglycerides [45,46]. Recently, evidence was provided that induction of the PGC1α−/−PPARα−/−target genes axis during fasting in liver is mediated by the basic helix–loop–helix (bHLH) leucine zipper transcription factor TFEB, which itself is induced by fasting [47].

2.2. Pharmacological and toxicological PPARα activation

2.2.1. Fibrates are high affinity PPARα activators

Besides binding a range of endogenous ligands, PPARα also serves as receptor for a diverse array of synthetic compounds collectively referred to as peroxisome proliferators that include phthalates, insecticides, herbicides, surfactants, organic solvents, and hypolipidemic fibrate drugs [1,48]. The latter group encompasses the compounds Wy14643, fenofibrate, clofibrate, ciprofibrate, bezafibrate and gemfibrozil. Synthetic PPARα agonists cause hepatomegaly and peroxisome proliferation in mice but not in humans [49] (Table 2). In humans, fibrates raise plasma HDL and reduce plasma triglycerides and therefore carry therapeutic value in the treatment of dyslipidemia [50]. Accordingly, most of the literature on fibrates is related to their clinical and pre-clinical effects on circulating cardiovascular disease risk factors and lipid metabolic parameters [51]. Chronic administration of peroxisome proliferators to rodents leads to hepatic carcinogenesis via PPARα [52], which has led to concerns about the industrial use of peroxisome proliferators and the potential carcinogenicity of these compounds in humans [53].

2.2.2. Rixinoids activate PPARα−RXR heterodimers

Consistent with PPARα−RXR functioning as a permissive heterodimer, RXR activation using the synthetic rixinoid LG1069 leads to upregulation of a large number of PPARα target genes in liver and heart [54,55], a response that is abolished in mice lacking PPARα [56,57]. Comparison of the effect of LG1069 and WY14643 in rodent liver reveals a marked resemblance in gene regulation by the two compounds, with many genes being induced by both agonists, including well established PPARα targets such as Acot1, Aca1, Ehhadh, Cpt2 and Plin2 [35,55]. By contrast, we found that LG1069 activates a distinct set of genes in primary human hepatocytes as compared with fenofibrate and WY14643, with minimal overlap (our unpublished data).

2.2.3. Regulation of hepatic lipid homeostasis by synthetic PPARα agonists

Numerous in vitro studies in cultured hepatocytes have demonstrated a stimulatory effect of synthetic PPARα agonists on peroxisomal and mitochondrial fatty acid oxidation [58–61]. Similarly, treatment of rodents with synthetic PPARα agonists markedly induces peroxisomal and mitochondrial fatty acid oxidation in liver homogenates and isolated hepatocytes, concurrent with an increase in size and number of peroxisomes, as well as increased activity of fatty acid oxidative enzymes such as carnitine palmitoyl-transferase, 2,4-dienoyl-CoA reductase, peroxisomal 3-ketoacyl-CoA thiolase, and acyl-CoA dehydrogenase [61–69]. Induction of fatty acid oxidative enzyme activity by PPARα agonists is paralleled by marked upregulation of the corresponding genes Cpt1a, Decr2, Aca1a, and Acad1 [35,70–72], as well as numerous other genes participating in fatty acid oxidation. The stimulatory effect of in vivo fibrate treatment on fatty acid oxidation and oxidative enzymes can be detected in isolated mitochondria and peroxisomes [73–76]. Besides mitochondrial and peroxisomal fatty acid oxidation, fibrates also stimulate hepatic microsomal omega-hydroxylation of fatty acids [75,77–79]. In addition, fibrates markedly induce ketogenesis in cultured hepatocytes and rodent livers [68,73,80–82]. Stimulation of fatty acid oxidation likely accounts for the beneficial effect of synthetic PPARα agonists on fatty liver in rats and mice [83–91], and may contribute to lowering of VLDL-triglyceride secretion [83], giving rise to their hypotriglyceridemic effect. It should be mentioned that in humans synthetic PPARα agonists primarily lower circulating triglycerides by stimulating plasma triglyceride clearance [83,92]. Intriguingly, pharmacological PPARα activation also stimulates hepatic de novo lipogenesis and chain elongation, as determined using stable isotopes [93]. Induction of lipogenesis by (chronic) fenofibrate treatment depends on sterol regulatory element-binding protein 1c (SREBP-
2.2.4. Regulation of hepatic glucose homeostasis by synthetic PPARγ agonists

There is limited evidence linking pharmacological PPARγ activation to regulation of glucose homeostasis. Whereas clofibrate lowers fasting glucose and insulin level and improves glucose tolerance and utilization in rodents [86,94–96] and humans [97–100], indicating enhancement of insulin sensitivity, fenofibrate does not have any effect on insulin sensitivity in humans [92,101–104]. It can thus be argued that the effect of clofibrate may be independent of PPARγ activation. Alternatively, the differential impact of clofibrate and fenofibrate on glucose homeostasis may be linked to selective PPAR modulation (SPPARM), based on the notion that different PPAR agonists may induce differential gene expression patterns via selective receptor—coregulator interactions.

At the intracellular level, fenofibrate treatment was found to reduce the contribution of glycolysis to acetyl-CoA production [93], which may be mediated by PPARγ-mediated induction of pyruvate dehydrogenase kinase 4 (Pdk4) [105]. Pdk4 phosphorylates and inactivates pyruvate dehydrogenase, thereby limiting carbon flux through glycolysis. Additional information about the impact of pharmacological PPARγ activation on intracellular glucose metabolism in liver and relevant mechanisms is lacking.

2.2.5. Regulation of hepatic amino acid metabolism by synthetic PPARγ agonists

Pharmacological PPARγ activation has a significant influence on amino acid metabolism. Specifically, hepatic gene expression of numerous enzymes involved in amino acid metabolism and urea synthesis is markedly decreased upon treatment of rodents with the PPARγ agonists Wy14643 or perfluorooctanoic acid (PFOA), including Got1, Asl, Ass1, Gis2, and Otc [38,106]. Downregulation of the corresponding proteins by synthetic PPARγ agonists in mice [107], rats [108], and dogs [109], is supported by proteomics analysis. In agreement with impaired ureagenesis, plasma ammonia levels were elevated in rats fed Wy14643 [110]. For reasons that are unclear, plasma urea levels were increased by Wy14643 as well [110].

In contrast to what is observed in rodents, PPARγ agonists directly upregulate expression of aspartate aminotransferase (Got1) and alanine aminotransferase (Gpt) in human hepatocytes and human HepG2 hepatoma cells (Table 2) [111–113], which may explain the elevated serum aspartate and alanine aminotransferase activities in PPARγ agonists-treated subjects that do not show further signs of liver injury. In fact, there is evidence that Gpt is a direct PPARγ target in human hepatocytes [112]. So far, the molecular basis for differential regulation of aminotransferases between mouse and human has remained elusive.

2.3. Nutritional PPARγ activation

2.3.1. Fatty acids and various fatty acid derivatives serve as PPARγ agonists

Several studies have demonstrated that PPARγ is able to bind fatty acids with a general preference for long-chain poly-unsaturated fatty acids (PUFAs) [40,48,114–120]. Furthermore, numerous fatty acid-derived compounds and compounds showing a structural resemblance to fatty acids, including oxidized fatty acids, eicosanoids, endocannabinoids, and phytic acid, are able to activate PPARγ [121–126]. In addition, biochemical studies indicate that fatty acyl-CoAs can bind PPARγ. Interestingly, it was found that they oppose the effects of Wy14643 and fatty acids on PPARγ conformation, DNA binding, and co-activator interaction, suggesting fatty acyl-CoAs serve as PPARγ antagonists. However, the in vivo relevance of acyl-CoAs as PPARγ ligands remains uncertain [125,127,128]. The combined evidence strongly suggests that PPARγ serves as a general fatty acid sensor with a limited degree of ligand selectivity. In addition, there are reports postulating that PPARγ may be activated by specific phospholipid species, including the phosphatidylcholines PC(16:0/18:1) or PC(18:0/18:1) [129,130]. Because phosphatidylcholines are abundant in any cell, and likely fluctuate very little, it is unclear how activation of PPARγ by phosphatidylcholines fits into the notion of PPARγ being a metabolic sensor.

Activation of PPARγ by fatty acids and fatty acid derivatives not only depends on their absolute concentration in the cell but also by the abundance of fatty acid–binding proteins such as Fabp1. Fabp1 was found to transfer fatty acids to the nucleus and co-localize with PPARγ [131,132]. Subsequent studies revealed that Fabp1 physically interacts with PPARγ and enhances PPARγ-dependent gene regulation [133–135].

2.3.2. Activation of PPARγ by high fat ketogenic diets

Studies using in vivo PPAR-reporter mice have suggested that PPARγ is activated by chronic high fat feeding [39]. Gene expression analysis of PPARγ target genes has confirmed modest activation of PPARγ in response to high fat feeding [136–140]. A complicating factor is that chronic high fat feeding also invariably causes hepatic steatosis, which is associated with induction of PPARγ and may therefore lead to induction of PPARγ target genes via PPARγ [137,141–143]. An extreme form of high fat diet that potently induces expression of PPARγ target genes in liver, including Fgf21, Cd36, Pdk4, Acadm, and Pex11a, is the ketogenic diet [144,145]. A ketogenic diet is almost entirely devoid of carbohydrate and elicits a metabolic state of low insulin, high plasma free fatty acids, and enhanced ketogenesis, that resembles fasting.

Similar to what is observed during fasting, the metabolic phenotype of PPARγ−/− mice becomes much more prominent upon feeding a ketogenic diet, illustrated by pronounced hepatic steatosis, hypoglycemia and elevated plasma FFA [144]. Overall, the extent of PPARγ activation by high fat feeding will likely depend on three main variables: the amount of fat in the diet in comparison with the control diet, the amount of sucrose in the diet in comparison with the control diet, and the amount of fat in the diet in comparison with the control diet, and the fatty acid composition of the diet. The lower the amount of sucrose and the higher the proportion ofpoly-unsaturated fatty acids, the stronger the activation of PPARγ.

2.3.3. Preferential activation of PPARγ by long chain poly-unsaturated fatty acids

As indicated above, diets rich in poly-unsaturated fatty acids lead to more pronounced PPARγ activation in liver compared to diets rich in saturated or mono-unsaturated fatty acids, as determined by measurement of enzyme activity or mRNA expression of target genes. Strongest activation of PPARγ is observed when feeding fish oil [90,146–150]. The potency of fish oil towards PPARγ is corroborated by oral lipid loading experiments in which mice received a single bolus of triglyceride composed of one single fatty acid [119]. A single oral fat load, which mimics a high fat meal low in carbohydrate, markedly and very specifically activates PPARγ in liver, with docosahexanoic acid being the most potent fatty acid, followed by linoleic acid, linoleic acid and oleic acid. The dietary fatty acids mostly copy the effects of high affinity synthetic PPARγ agonists, except that they are much less
potent [119]. These findings demonstrate that dietary fatty acids are able to activate hepatic PPARα after their delivery to the liver as part of chylomicron remnants. The large hydrophobic binding cavity allows PPARs to interact with a variety of structurally related and unrelated compounds [151]. Indeed, apart from fatty acids, numerous other dietary components have been proposed to serve as PPARα agonists, including but not limited to the flavonoid cyanidin [152], the carotenoid astaxanthin [153], the plant triterpenoid ursolic acid [154], the plant stilbenoid pterostilbene [155], isohumulones in hops [156], soy isoflavones [157], and conjugated linoleic acid [158]. However, it is highly questionable whether intake of any of these compounds is high enough to lead to PPARα activation in vivo, especially taking into account the abundance of fatty acids in our diet and in the cell.

3. TARGET GENES AND PATHWAYS OF PPARα

3.1. Overview of PPARα-mediated gene regulation

3.1.1. Pharmacological versus physiological PPARα target genes

PPARα governs biological processes by altering the expression of a large number of target genes. Gene expression profiling studies have indicated that PPARα target genes number in the hundreds [35,119,159], which is similar to other liver-enriched nuclear receptors such as LXR [160]. Accordingly, the functional role of PPARα is directly related to the biological function of its target genes. However, it should be realized that the influence of PPARα on gene regulation is dependent on whether PPARα is activated pharmacologically, physiologically, or nutritionally. Fibrates not only bind to PPARα more avidly compared with fatty acids [48,161], but likely also cause a slightly different conformational change in the PPARα protein as dictated by the SPPARM concept [119], together leading to slightly altered and generally more robust induction of target genes by fibrates. Furthermore, the endocrine profile and thereby the general chromatin and transcriptional landscape supporting PPARα-dependent gene regulation can be different depending on feeding status. Nevertheless, for the most part the genes induced by fibrates are the same genes that are reduced in PPARα−/− mice in the fasted state [35] (Figure 3). The similarity in gene regulation by PPARα upon pharmacological and physiological activation is well illustrated by gene set enrichment analysis (GSEA), showing large overlap in enriched gene sets between the two conditions (Figure 4). Major exceptions are genes involved in bile synthesis and secretion, many of which are markedly downregulated in PPARα−/− mice in the fasted state yet are not induced by fibrates (Figure 3). The same is true for several genes involved in retinoid metabolism. The exclusive regulation of retinol metabolism and bile secretion by PPARα during fasting is confirmed by GSEA (Figure 4). It is possible that this pattern of gene regulation may reflect indirect regulation, e.g. genes that are reduced in fasted PPARα−/− mice but that are not induced by synthetic PPARα agonists may not be direct targets of PPARα. The opposite is also observed: a number of genes are significantly induced by fibrates but are not decreased in PPARα−/− mice in the fasted state [42]. Several potential explanations for this type of regulation can be put forward. A) Induction of the gene by fibrates reflects regulation in Kupffer cells [162]. In contrast to hepatocytes, PPARα in Kupffer cells is most likely not activated by fasting. For example, PPARα is specifically expressed in Kupffer cells and is markedly induced by fibrates, yet expression is unchanged by PPARα deletion in the fasted state. B) The elevated plasma FFA levels in fasted PPARα−/− mice lead to induction of other transcription factors, such as PPARδ, obscuring a potential role of PPARα in regulation of these genes in the fasted state [42]. Genes in this category include Lpin2, Plin3, and Pdk4.

C) As mentioned above, high affinity activation of PPARα may cause differential recruitment of co-factors (SPPARM) compared with physiological PPARα activation, resulting in subtle differences in gene regulation. D) Certain genes are relatively weak targets of PPARα characterized by low affinity PPREs and therefore require a fully activated PPARα to show any mRNA induction.

3.1.2. Detailed map of PPARα-mediated gene regulation

Gene expression analysis of livers of PPARα−/− mice at the level of individual genes or the entire genome via transcriptomics has indicated that PPARα governs many aspects of hepatic lipid metabolism, providing a molecular basis for the pronounced metabolic disturbances in fasted PPARα−/− mice and explaining the marked impact of synthetic PPARα agonist on lipid metabolism [163,164]. To capture the scope of PPARα activity in liver and to illustrate the role of PPARα in transcriptional regulation of liver (lipid) metabolism, a detailed regulatory map was created of metabolic genes upregulated by PPARα, separated according to metabolic pathway (Figure 3). A distinction is made between genes regulated by PPARα during fasting (in green), by synthetic PPARα agonist (in blue), or both (in red). Many of the genes shown in Figure 3 and described in the text below are direct PPARα target genes based on the presence of a functional PPRE, as determined by transactivation assay, gel shift, and/or genomic DNA binding by chromatin immunoprecipitation. However, this criteria was not applied very strictly was assigning PPARα target gene status, under the assumption that genes showing strong functional resemblance to known PPARα targets and that are significantly upregulated upon PPARα activation and/or significantly downregulated upon PPARα deletion most likely represent direct target genes, despite the fact that a functional PPRE has not (yet) been located. Genes in that category include Acadvl, Hadha, and Etfdh. Because of these relatively loose criteria, it cannot be excluded that some of the genes shown are indirectly regulated by PPARα. Indeed, several putative targets of PPARα are also regulated by CREB3L3, a transcription factor that is under strong transcriptional control of PPARα, including Fgf21, Gys2, Elov12, Elov15, Bdh1, G0s2, Mgl1, Decr2, and Cidec [159,165]. Some of these genes have previously been identified as direct PPARα targets based on the presence of a functional PPRE, including Fgf21, Gys2, and G0s2 [33,166–168], suggesting possible dual regulation by PPARα and CREB3L3. In fact, recent data suggest that CREB3L3 and PPARα form a transcriptional complex, which binds to an integrated CRE–PPRE binding motif in the FGF21 gene promoter [169]. Whether CREB3L3 is more broadly involved in target gene regulation by PPARα is a very intriguing question that deserves further exploration. Other transcription factors that cooperate with PPARα or are under transcriptional control of PPARα, and thus may mediate effects of PPARα on gene expression include KLF11 (Cyp1a1, Cyp4a10, Cyp4a14, Acadm) and KLF10 (Cyp4a14, Gpm, Acot3, Retnsb) [159,170,171]. In the above situations, PPARα indirectly upregulates gene expression without binding to a canonical PPRE. Other PPRE-independent mechanisms of gene regulation by PPARα include physical interaction with other transcription factors, which can either be stimulatory or inhibitory (transpression), and physical interactions with co-activators leading to reduced availability of those co-activators for other transcription factor pathways (squelching, inhibitory) [172].

3.1.3. PPARα cistrome

The PPARα cistrome is defined as the in vivo genome-wide location of PPARα binding-sites, as determined using ChIP-SEQ and ChIP-on-CHIP. Interestingly, these analyses have found relatively little overlap
between induction of gene expression by the PPARα agonist GW7647 and the GW7647-induced binding of PPARα to a PPRE in the proximity of the gene, at least in primary human hepatocytes and HepG2 cells [173,174]. These data suggest significant uncoupling between gene induction by PPARα and the binding of PPARα to the gene, thus pointing at other mechanisms of gene (up)regulation by PPARα.

However, this conclusion may be partially confounded by the likely flawed assumption that binding of ligand enhances PPARα binding to DNA and that PPAR binding sites are located within a certain distance of the transcriptional start site. Profiling of genomic binding sites of PPARα in human HepG2 cells by ChIP-on-CHIP analysis raised the possibility that PPARα may be recruited to certain gene promoters via direct physical interaction with other transcription factors [174]. In agreement with this notion, ChIP-SEQ revealed extensive overlap in genomic binding sites of LXR and PPARα [175]. The consequences of the LXR and PPARα overlap with respect to gene regulation seem to be determined by the context of the genomic binding site(s) and the activity of the individual receptors at the particular sites, suggesting that cross talk is context dependent and probably not due to competition for RXR [175].

Despite the overall usefulness of information on PPARα cistrome towards enhancing our understanding of the determinants of genomic binding by PPARα, its value for specific gene regulation by PPARα and assigning PPARα target gene status has so far been limited.

3.2. Target genes of PPARα in hepatic lipid metabolism

3.2.1. Fatty acid uptake, binding and activation

The mechanism of fatty acid uptake into hepatocytes remains poorly defined but a (partial) role for the fatty acid translocase Cd36 is likely. Cd36 is upregulated by PPARα [176], as are the putative fatty acid transporters Fatp2 and Fatp4 [35,176,177]. Because they are localized to the ER and thus cannot mediate membrane fatty acid transport directly, Fatp2 and Fatp4 seem to stimulate fatty acid uptake into hepatocytes indirectly via their acyl-CoA synthetase activity [178]. Acyl-Co synthetase activity is necessary to convert fatty acids to their acyl-CoA derivatives via thio-esterification, which is an essential step for directing fatty acids towards specific metabolic pathways. Several cytosolic acyl-Co synthetases are under transcriptional control of PPARα, including Acsl1 and Acsl5 [35,179–181]. Interestingly, expression of the cytosolic Acyl-coenzyme A thio-esterases Acot1 and Acot7, which catalyze the reverse reaction and together with acyl-Co synthetases determine the balance between cytoplasmic concentrations of acyl-CoAs, free CoA and fatty acids, is also upregulated by PPARα [182].

The FABP gene family comprises a group of high-affinity intracellular fatty acid-binding proteins. Fabp1 (L-FABP) was one of the first PPARα target genes identified [183–185], and is highly abundant in liver. Fabp1 is likely involved in partitioning of fatty acids to specific lipid metabolism.
metabolic pathways [186]. Other Fabp genes induced by PPARα activation in mouse liver include Fabp2 (I-FABP) and Fabp4 (A-FABP, aP2), whose role in liver is uncertain.

3.2.2. Peroxisomal fatty acid oxidation

The first identified target gene of PPARα was Acyl-CoA oxidase (Acox1), which encodes the first enzyme in peroxisomal long-chain fatty acid oxidation [2,5]. Peroxisomes are involved in many lipid metabolic pathways, including synthesis of bile acids and plasmalogens, synthesis of cholesterol and isoprenoids, alpha-oxidation, glyoxylate and H2O2 metabolism, and β-oxidation of very-long-straight-chain or branched-chain acyl-CoAs. Many aspects of peroxisomal fatty acid metabolism are under transcriptional control of PPARα including peroxisomal fatty acid uptake (Abcd1, Abcd2 and Abcd3).

Figure 4: Pathways upregulated by PPARα during fasting or by Wy14643. Gene set enrichment analysis was performed on transcriptomics data comparing livers from 24 h fasted PPARα+/+ and 24 h fasted PPARα−/− mice (A), or livers from wildtype mice treated with Wy14643 or treated with vehicle for 5 days (B). The top 20 most significantly enriched (upregulated) gene sets are shown ranked according to normalized enrichment score.

Figure 5: Detailed overview map of metabolic genes upregulated by PPARα in human hepatocytes. The map is based on the published literature, including transcriptomics analysis of primary human hepatocytes treated with synthetic PPARα agonists.
conversion of acyl-CoA/acyethyl-CoA to acetyl-carnitine/acyethyl-carnitine (Cot/Crat) [35], and conversion of acetyl-CoAs back to fatty acids via numerous thioesterases (Acots) [35,190]. Thioesterase and acetyl-carnitine transferase activities are likely required for transporting fatty acids of various chain length out of the peroxisomes for further oxidation in mitochondria. Apart from Acocx1, the enzymes operating downstream from Acocx1 in peroxisomal β-oxidation of acetyl-CoAs are also all target genes of PPARα. These enzymes carry enoyl-CoA-hydratase and 3-hydroxacyl-CoA dehydrogenase activity (L-bifunctional enzyme, Ehhdh; D-bifunctional enzyme, Hsd17b4), and peroxisomal 3-ketoacyl-CoA thiolase activity (Acaa1a, Acaa1b) [179,191–193]. Finally, expression of numerous genes involved in import of peroxisomal proteins and thus peroxisome assembly, referred to as the Pex family, are transcriptionally regulated by PPARα [159,194]. Induction of the above mentioned genes accounts for the massive proliferation of peroxisomes observed in rodents exposed to synthetic PPARα agonists.

3.2.3. Mitochondrial fatty acid oxidation

Almost every single enzymatic step in mitochondrial uptake and subsequent oxidative breakdown of acyl-CoAs to acetyl-CoA is regulated by PPARα. Specifically, PPARα stimulates acetyl-CoA import into the mitochondria by upregulating expression of carnitine palmitoyl-transferases 1a, 1b and 2 (Cpt1a, Cpt1b, Cpt2), and the acyl-carnitine translocase (Slc25a20) [195,196]. Furthermore, PPARα upregulates expression of genes involved in cellular uptake and biosynthesis of carnitine (Aldh9a1, Bbox1, Slc22a5) [35,197,198]. Decreased expression of carnitine biosynthetic genes explains the reduced total carnitine levels in plasma and liver of PPARα−/− mice [27].

In the first step of β-oxidation, acetyl-CoA is dehydrogenated in a PPARα-induced reaction catalyzed by a family of four closely related and chain-length-specific enzymes, the acyl-CoA dehydrogenases (Acadvl, Acad2, Acadm, Acads) [179,199]. The three subsequent steps in β-oxidation leading to chain shortening and release of acetyl-CoA are catalyzed by the mitochondrial trifunctional enzyme (Hadh3 and Hadh1). Upon progressive chain shortening, two other enzymes (Hadh, Acad2) take over the function of trifunctional enzyme, both of which are PPARα targets, as are the enzymes required to convert unsaturated and 2-methylated acyl-CoAs into intermediates of β-oxidation (EC1, Eci2, Decr1, Hsd17b10) [119,179]. Other highly suspected PPARα target genes linked to fat oxidation include a set of poorly characterized acyl-CoA dehydrogenases (Acad8, Acad10 and Acad11), and electron transfer flavoprotein beta (Etfb) and electron transfer flavoprotein dehydrogenase (Etfdh), which shuttle electrons from acyl-CoA dehydrogenases to the electron transport chain [35,200]. Under certain metabolic conditions such as fasting, excess acetyl-CoA generated via β-oxidation feeds into ketogenesis, a pathway reliant on four enzymes (Acat1, Hmgcs2, Hmgcl, Bdh1). All are transcriptional targets of PPARα, with Hmgcs2 as the best described representative [201].

3.2.4. Microsomal fatty acid oxidation

Cytochrome P450 monooxygenase (CYP4A) enzymes involved in microsomal ω-hydroxylation of fatty acids are among the most sensitive target genes of PPARα [202,203]. Studies using PPARα−/− mice have shown that hepatic expression of Cyp4a genes is almost completely abolished in the absence of PPARα (Cyp4a10, Cyp4a12, Cyp4a14 in mice, Cyp4a11 in human) [137]. The Cyp4A family members exhibit highest activity for lauric acid, with activity decreasing with increasing fatty acid chain length, whereas the Cyp4F family is active towards eicosanoids and xenobiotics [204].

3.2.5. Lipid storage and hydrolysis

Activation of fatty acid oxidation by PPARα is well established but the stimulatory effect of PPARα on several other lipid metabolic pathways is less well recognized. Compelling evidence from microarrays indicates that pharmacological and/or physiological activation of PPARα leads to upregulation of numerous genes involved in fatty acid elongation (Elov family) and desaturation (Scd1) [35,205]. In addition, PPARα induces expression of a number of enzymes in the triglyceride biosynthesis pathway (Gpam, Lpin2, Dagl1), albeit primarily upon pharmacological activation of the receptor [35,42]. Concurrent with induction of triglyceride synthesis, enzymes required for intracellular triglyceride hydrolysis are upregulated by PPARα as well, including monoglyceride lipase Mgl, the triglyceride lipase Pnpla2 and the Pnpla2 inhibitor G6s2 [35,168,206,207]. Finally, several proteins that are physically and functionally associated with lipid droplets are direct targets of PPARα in liver. These include Pli1 [208,209], Pli4 [42,210], Pli5 [211,212], Ftm1 [213], Cidea [214], and Cidec [35,173,215]. Most of the genes encoding lipid-droplet associated proteins are specifically induced by pharmacological PPARα activation and show no regulation by PPARα during fasting. Detailed insight into the biochemical role of the various lipid-droplet associated proteins is currently lacking, rendering assessment of the functional impact of their regulation by PPARα challenging.

It is well recognized that loss of PPARα worsens hepatic steatosis, particularly during fasting and high fat feeding [21,22,216,217], whereas PPARα activation reduces steatosis [83–91]. In general, it is difficult to tie the diverse effects of PPARα on lipases, lipid droplet associated proteins, elongases, and enzymes involved in triglyceride synthesis together into a coherent functional model that aligns with the PPARα-induced changes in intracellular lipid storage. Furthermore, the overarching physiological rationale for activation of these pathways by PPARα remains ambiguous. It can be hypothesized that induction of genes involved in triglyceride synthesis such as Gpam by PPARα during fasting may reflect a broader role of PPARα in metabolizing and neutralizing large amounts of incoming adipose tissue-derived free fatty acids.

3.2.6. Bile synthesis and secretion

Numerous genes involved in bile synthesis and secretion are reduced in fasted PPARα−/− mice compared with fasted wildtype mice. This includes genes involved in phospholipid synthesis (Lpcat3) [218,219], secretion of cholesterol and phospholipids into bile (Abcg5, Abcg8, Abcb4) [35,220,221], genes mediating bile acid uptake (Slc10a1 = Ntcp) and excretion (Abcc3 = Mrp3), and genes promoting bile acid synthesis (Cyp7a1, Cyp8b1, Nr1h4 = Fxr) [168,220,222]. Furthermore, PPARα regulates cholesterol uptake and export via Scarb1 and Abca1, respectively [220,223]. Most of these genes are uniquely regulated by PPARα during fasting, with the exception of Nceh1, Abca1 and Abcb4, which are also induced upon pharmacological PPARα activation. Despite being a direct PPARα target gene in macrophages [224,225], Scarb1 protein and mRNA levels are significantly decreased by liprates in liver [226]. Expression of Cyp7a1, encoding the purported rate-limiting enzyme in bile acid synthesis, is markedly downregulated in PPARα−/− mice during fasting [222]. Paradoxically, Cyp7a1 mRNA and activity are also markedly reduced by synthetic PPARα agonists in rodents and humans [227–232]. Consistent with an important role of PPARα in the regulation of many genes implicated in bile acid metabolism, plasma and liver levels of bile acids are elevated in PPARα−/− mice when challenged with dietary cholic acid [233]. A detailed review of the impact of PPARα on bile acid homeostasis is provided elsewhere [234]. Overall, what is clear is that unlike for the peroxisomal and mitochondrial fatty
acid oxidation pathway, the direction of the impact of PPARα on genes involved in bile acid homeostasis is highly dependent on the mode of PPARα activation.

3.2.7. Retinoid metabolism

Conversion of retinol to retinal and retinoic acid is catalyzed by a number of enzymes, of which the corresponding genes are subject to PPARα stimulation during fasting (Dhrs3, Dhrs4, Adh1, Adh4, Aldh1a1) [236]. 9-cis retinoic acid serves as a ligand for the PPARα permissive binding partner RXR, suggesting that stimulation of retinoic acid synthesis by PPARα may further increase transcriptional activation by PPARα. Conversion of retinol to all-trans 13,14 dehydroretinol is catalyzed by retinol saturase (RetSat), a direct target gene of PPARα [236]. Currently, the actual function of RetSat in liver is not clear.

3.3. Target genes of PPARα in other metabolic pathways

3.3.1. Glucose metabolism

As described previously, PPARα activation and deletion are associated with major changes in glucose metabolism. A number of genes in the hepatic gluconeogenesis pathway are known or very likely PPARα targets, including pyruvate carboxylase (Pcx), and fructose bisphosphate 1 [35,237,238]. Phosphoenol pyruvate carboxykinase (Pck1) appears to be specifically regulated by PPARα in human but not mouse hepatocytes [24,159]. Adipose tissue lipolysis leads to elevated circulating levels of glycerol, which is processed in the liver. Importantly, numerous genes involved in the metabolic conversion of glycerol in liver such as Gpd1, Gpd2, Gyk, Aqp3, and Aqp9, are targets of PPARα [24]. Besides governing glucose production, PPARα may also alter glucose utilization in numerous tissues via induction of pyruvate dehydrogenase kinase isofrom 1 and 4 (Pdk1, Pdk4) [25,239]. Finally, glycogen synthesis in liver is targeted by PPARα via regulation of Gys2, the liver and adipose tissue-specific glycogen synthase isofrom [33].

3.3.2. Secreted factors

Apart from direct regulation of genes encoding key enzymes in fatty acid oxidation and ketogenesis, it has been suggested that PPARα may partially stimulate these pathways indirectly via upregulation of the sensitive PPARα target and hormone FGF21 [144,166,167]. Importantly, many classical PPARα targets, including Acox1-4, Ehhadh, Cpt1α, Cpt1β, Cpt2, Hmgcs2, and Hadha, can be induced by PPARα activation in cultured mouse liver slices in the absence of any changes in FGF21, indicating that FGF21 is not essential for induction of genes involved in fatty acid oxidation and ketogenesis by PPARα. How FGF21 induces these pathways remains unclear but its effects are thus clearly distinct from direct gene regulation by PPARα and likely involve extrahepatic tissues [240,241]. Other secreted factors that may mediate extra-hepatic actions of PPARα during fasting include Angiopoietin-like 4 (ANGPTL4), Mannose Binding Lectin (MBL2), and Fibroblast Growth Factor (FGF1) [242—244]. Fgf1 was recently identified as target of PPARγ in adipose tissue but is also transcriptionally regulated by PPARα in liver [242]. ANGPTL4 is an endogenous inhibitor of lipoprotein lipase that regulates tissue uptake of plasma TG-derived fatty acids [245], whereas MBL2 is a soluble mediator of innate immunity and primary component of the lectin branch of the complement system [244,246].

3.3.3. Vanin-1

One of the most highly induced genes upon PPARα activation in liver is Vanin-1 (Vnn1), which encodes a glycosylphosphatidylinositol-linked membrane-associated pantetheinase that catalyzes the hydrolysis of pantetheine into pantothentic acid (vitamin B5) and cysteamine. Multiples lines of experimentation clearly demonstrate that Vnn1 is a direct PPARα target gene [184,247]. Vanin-1 is present in plasma and determination of Vanin-1 activity and protein abundance was found to accurately reflect PPARα activation in liver, indicating that serum Vanin-1 may be used as a reliable reporter of hepatic PPARα activity in mice and humans [247,248].

3.4. Similarity in gene regulation by PPARα between mouse and human

Befitting their name, peroxisome proliferators and other synthetic PPARα agonists cause proliferation of peroxisomes and hepatomegaly in rats and mice in a PPARα-dependent manner [49]. In contrast, neither response is observed in humans (Table 2), which together with the observed lack of effect of PPARα agonists on peroxisomal fatty acid oxidation in humans [249], has led to suggestions that the function of PPARα is fundamentally different between mice and humans, and, partly due to the presumed low expression of PPARα in human liver, that the role of PPARα in human liver is relatively insignificant [250]. Subsequent studies have dispelled those notions, showing that a) PPARα expression is similar in mouse and human liver, b) regulation of lipid metabolic pathways and genes, including peroxisomal fatty acid oxidation, is well conserved between mice and humans [159,173]. In addition, the clinical efficacy of synthetic PPARα agonists attests to the functional importance of PPARα in governing lipid metabolism in human. Nevertheless, a number of metabolic genes appear to be specifically regulated by PPARα in rodents and not humans (Figure 5). Putative rodent-specific PPARα target genes include Mgl1, Bbox1, Decr1, and Fbp2 [159]. It has been suggested that the first PPARα target Acyl-CoA oxidase is also a rodent-specific PPARα target, presumably due to the absence of a functional PPRE in the human ACOX1 gene [251]. However, gene expression profiling studies indicate that ACOX1 is one of the mostly significantly induced genes in human hepatocytes treated with synthetic PPARα agonists [159,173]. Conversely, a very small number of genes may be exclusively induced by PPARα in human liver cells, including PCK1, MBL2, APOA2 and possibly APOA5 [244,246,252]. With respect to APOA5, the human APOA5 gene has clearly been demonstrated to be a direct PPARα target characterized by a functional PPRE in its promoter [253]. Consistent with this finding, APOA5 mRNA is induced by PPARα activation in human and monkey hepatocytes, and APOA5 plasma levels are increased by treatment of monkeys with a synthetic PPARα agonist [173,253,254]. In contrast, Apoa5 upregulation is not observed in mouse liver or in cultured mouse hepatocytes, presumably due to a degenerate and non-functional PPRE in the mouse Apoa5 promoter [255]. Surprisingly, we found that Apoa5 mRNA is markedly and reproducibly induced by Wy14643 in mouse liver slices (our unpublished data), suggesting that Apoa5 may be a PPARα target in mouse after all, perhaps via the use of an alternative PPARα response element. Full understanding of the differences in PPARα-mediated gene regulation between mice and humans is hampered by practical limitations in the form of lack of (liver-derived) human livers. One of our future ambitions is to perform a whole genome comparison of the response to PPARα agonist in mouse and human cultured precision-cut liver slices, under the assumption that cultured liver tissue slices are superior to primary human hepatocytes for studying liver metabolism and gene regulation.

4. CONCLUSION

According to the traditional view, PPARα governs fatty acid oxidation and ketogenesis in liver. However, gene expression analysis at the
level of individual genes or the entire genome via transcriptomics has indicated that the role of PPARα extends to numerous other metabolic pathways, providing a molecular basis for the pronounced metabolic disturbances in fasted PPARα−/− mice and explaining the marked impact of synthetic PPARα agonists on lipid metabolism in rodents and humans. It is now evident that PPARα functions at the center of a regulatory hub impacting fatty acid uptake, fatty acid activation, intracellular fatty acid binding, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis, triglyceride turnover, lipid droplet biology, gluconeogenesis, and bile synthesis/secretion. In addition, PPARα governs the expression of several secreted proteins that exert local and endocrine functions. Hence, PPARα can aptly be described as a master regulator of hepatic lipid metabolism.

CONFLICT OF INTEREST

None declared.

REFERENCES

[1] Issemann, I., Green, S., 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645−650.
[2] Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., Wahli, W., 1992. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879−887.
[3] Chawla, A., Repa, J.J., Evans, R.M., Mangelsdorf, D.J., 2001. Nuclear receptors and lipid physiology: opening the X-receptor superfamily by peroxisome proliferators. Nature 347:645−650.
[4] Gronemeyer, H., Laudet, V., 1995. Transcription factors 3: nuclear receptors. Advances in Nutrition 3:127−130.
[5] Sugden, M.C., Bulmer, K., Gibbons, G.F., Knight, B.L., Holness, M.J., 2002. Peroxisome-proliferator-activated receptor-alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. Journal of Biological Chemistry 275:28918−28928.
[6] Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., Wahli, W., 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Journal of Clinical Investigation 103:1489−1498.
[7] Leon, T.C., Weinheimer, C.J., Kelly, D.P., 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proceedings of the National Academy of Sciences of the United States of America 96:7473−7478.
[8] Makowski, L., Noland, R.C., Koves, T.R., Xing, W., Ikuyama, O.R., Muhlbauer, M.J., et al., 2009. Metabolic profiling of PPARα−/− mice reveals defects in amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB Journal 23:586−604.
[9] Leslie, L.J., 2000. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Letters 475:163−166.
[10] Alhert, H.J., Gulston, M.K., Bailey, N.J., Cheng, K.K., Zhang, W., Clarke, K., et al., 2009. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Molecular Systems Biology 5:250.
Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 47:1032–1042.

Bandsma, R.H., Van Dijk, T.H., Harmsel At, A., Kok, T., Reijngoud, D.J., Staels, B., et al., 2004. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. Journal of Biological Chemistry 279:8930–8937.

Mandard, S., Slienstra, R., Escher, P., Tan, N.S., Kim, I., Gonzalez, F.J., et al., 2007. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. Cellular and Molecular Life Sciences 64:1145–1157.

Derks, T.G., van Dijk, T.H., Greffhorst, A., Rake, J.P., Smit, G.F., Kuipers, F., et al., 2008. Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 47:1032–1042.

Rakhshandehroo, M., Sanderson, L.M., Matilainen, M., Slienstra, R., Carberg, C., de Groot, P.J., et al., 2007. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Research 2007:26839.

Xu, J., Chang, V., Joseph, S.B., Trujillo, C., Bassilian, S., Saad, M.F., et al., 2004. Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-sensitivity of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 145:1087–1095.

Knauf, C., Rieuwert, J., Foret, M., Can, P.D., Udry, M., Hosokawa, M., et al., 2006. Peroxisome proliferator-activated receptor alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain. Endocrinology 147:4067–4078.

Kersten, S., Mandard, S., Escher, P., Gonzalez, F.J., Tafuri, S., Desvergne, B., et al., 2001. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB Journal 15:1917–1978.

Ciana, P., Biserni, A., Tatangelo, L., Tiveron, C., Sciarraioni, A.F., Ottobri, L., et al., 2007. A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Molecular Endocrinology 21:388–400.

Gottlicher, M., Widmark, E., Li, Q., Gustafsson, J.A., 1992. Fatty acids activate a chimera of the clofibrate-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 89:4653–4657.

Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., et al., 2005. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism 1:309–322.

Sanderson, L.M., Degenhardt, T., Koppen, A., Kalkhoven, E., Desvergne, B., Muller, M., et al., 2009. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Molecular and Cellular Biology 29:6257–6267.

Lemperger, T., Saladin, R., Vazquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., et al., 1996. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. Journal of Biological Chemistry 271:1764–1769.

Gachon, F., Leuenberger, N., Claudel, T., Gos, P., Jouffe, C., Fleury Olela, F., et al., 2011. Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPARalpha) activity. Proceedings of the National Academy of Sciences of the United States of America 108:4794–4799.

Haemannre, G., Mozafar, T., Woelkart, G., Buttnar, S., Schmidt, A., van de Weijer, T., et al., 2011. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nature Medicine 17:1076–1085.

Ong, K.T., Mashek, M.T., Bu, S.Y., Greenberg, A.S., Mashek, D.G., 2011. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 53:116–126.

Settembre, C., De Cegli, R., Mansuetto, G., Saha, P.K., Vetrini, F., Visvikis, O., et al., 2013. TFB3 controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nature Cell Biology 15:647–658.

Forman, B.M., Chen, J., Evans, R.M., 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America 94:4312–4317.

Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Krolez, D.L., et al., 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 15:3012–3022.

Duval, C., Muller, M., Kersten, S., 2007. PPARalpha and dyslipidemia. Biochimica et Biophysica Acta 1771:961–971.

Staels, B., Maes, M., Zambon, A., 2008. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nature clinical practice. Cardiovascular Medicine 5:542–553.

Peters, J.M., Cattley, R.C., Gonzalez, F.J., 1997. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18:2029–2033.

Gonzalez, F.J., 2002. The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. Molecular and Cellular Endocrinology 193:71–79.

Mukherjee, R., Strasser, J., Jow, L., Hoener, P., Paterniti Jr., J.R., Heyman, R.A., 1998. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arteriosclerosis Thrombosis and Vascular Biology 18:272–276.

Wang, Y., Yao, R., Maciag, A., Grubbs, C.J., Lubea, R.A., You, M., 2006. Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with tretinoin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Molecular Cancer Therapeutics 5:1060–1072.

Martin, P.G., Lasserre, F., Calleja, C., Van Es, A., Roulet, A., Concordet, J., et al., 2005. Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks. Gene Expression 12:177–192.

Ouamarrane, L., Larrieu, G., Gauthier, B., Pineau, T., 2003. RXR activators molecular signalling: involvement of a PPAR alpha-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart. British Journal of Pharmacology 138:845–854.

Corru-Chagnon, M.C., Dupont, H., Edgar, A., 1995. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology 26:63–74.

Gray, T.J., Lake, B.G., Beamand, J.A., Foster, J.R., Gangolli, S.D., 1983. Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology 67:15–25.

Lake, B.G., Gray, T.J., Pels Rijcken, W.R., Beamand, J.A., Gangolli, S.D., 1984. The effect of hypolipidaemic agents on peroxisomal beta-oxidation and mix-function oxidase activities in primary cultures of rat hepatocytes. Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation. Xenobiotics: the Fate of Foreign Compounds in Biological Systems 14:269–276.

Paul, H.S., Adibi, S.A., 1979. Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myostatin and alteration of fatty acid and glucose oxidation. Journal of Clinical Investigation 64:405–412.

Furuta, S., Miyazawa, S., Hashimoto, T., 1984. Induction of acyl-CoA dehydrogenases and electron transfer flavoprotein and their roles in fatty acid oxidation in rat liver mitochondria. Journal of Biochemistry 90:1751–1756.

Glitz, J.F., Wagenmakers, A.J., Veerkamp, J.H., van Moerkerk, H.T., 1983. Effect of clofibrate feeding on palmitate and branched-chain 2-oxo acid oxidation in rat liver and muscle. Biochemical Pharmacology 32:2489–2493.

Kahonen, M.T., Ylikahri, R.H., 1979. Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose–response relations. Atherosclerosis 32:47–56.
Review

[65] Kawashima, Y., Katoh, H., Watanuki, H., Takegishi, M., Kozuka, H., 1985. Effects of long-term administration of clofibrate acid on peroxisomal beta-oxidation, fatty acid-binding protein and cytosolic long-chain acyl-CoA hydrolases in rat liver. Biochemical Pharmacology 34:325–329.

[66] Mannaerts, G.P., Debeer, L.J., Thomas, J., De Schepper, P.J., 1979. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. Journal of Biological Chemistry 254:4585–4595.

[67] Mortensen, P.B., Rasmussen, K., 1983. Beta-oxidation of C-6-C-10 fatty acids in rat liver homogenates measured by selected ion monitoring: effects of cyanide and clofibrate. Biomedical Mass Spectrometry 10:528–533.

[68] Pande, S.V., Parvin, R., 1980. Clofibrate enhancement of mitochondrial carnitine transport system of rat liver and augmentation of liver carnitine and gamma-butyrobetaine hydroxylation activity by thyrnoxin. Biochimica et Biophysica Acta 617:363–370.

[69] Reddy, M.K., Lalwani, N.D., Gureshi, S.A., Reddy, J.K., 1982. Induction of hamster hepatic peroxisomal beta-oxidation and peroxisome proliferation-associated 80000 mol. wt. polypeptide by hypolipidemic drugs. Human Toxicology 1:135–147.

[70] Bodnar, A.G., Rachubinski, R.A., 1990. Cloning and sequence determination of cDNA encoding a second rat liver peroxisomal 3-ketoacyl-CoA thiolase. Gene 91:193–199.

[71] Ozasa, H., Miyazawa, S., Furuta, S., Osumi, T., Hashimoto, T., 1985. Induction of peroxisomal beta-oxidation enzymes in primary cultured rat hepatocytes by clofibrate acid. Journal of Biochemistry 97:1273–1278.

[72] Reddy, J.K., Coel, S.K., Nemali, M.R., Carrino, J.J., Laffier, T.G., Reddy, M.K., et al., 1986. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proceedings of the National Academy of Sciences of the United States of America 83:1747–1751.

[73] Kahonen, M., 1979. Effect of clofibrate treatment on acylcarnitine oxidation in isolated rat liver mitochondria. Medical Biology 57:58–65.

[74] Lazarow, P.B., De Duve, C., 1976. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proceedings of the National Academy of Sciences of the United States of America 73:2043–2046.

[75] Osmundsen, H., Cervernak, J., Bremer, J., 1982. A role for 2,4-enoyl-CoA reductase in mitochondrial beta-oxidation of polyunsaturated fatty acids. Effects of treatment with clofibrate on oxidation of polyunsaturated acylcarnitines by isolated rat liver mitochondria. Biochemical Journal 208:749–757.

[76] Veitch, K., Draye, J.P., Van Hoof, F., Sherratt, H.S., 1988. Effects of riboflavin deficiency and clofibrate treatment on the five acyl-CoA dehydrogenases in rat liver mitochondria. Biochemical Journal 244:477–481.

[77] Orton, T.C., Parker, G.L., 1982. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metabolism and Disposition: the Biological Fate of Chemicals 10:110–115.

[78] Sharma, R., Lake, B.G., Gibson, G.G., 1988. Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid beta-oxidation pathway in the rat by clofibrate and di-2-ethylhexylphosphoric acid. Dose-response studies. Biochemical Pharmacology 37:1203–1206.

[79] Sharma, R.K., Lake, B.G., Makowski, R., Bradshaw, T., Earnshaw, D., Dale, J.W., et al., 1989. Differential induction of peroxisomal and microsomal fatty-acid-oxidising enzymes by peroxisome proliferators in rat liver and kidney. Characterisation of a renal cytochrome P-450 and implications for peroxisome proliferation. European Journal of Biochemistry 184:69–78.

[80] Bergenthal, S., Christiansen, E.N., Bremer, J., 1986. The effect of feeding fish oils, vegetable oils and clofibrate on the ketogenesis from long chain fatty acids in hepatocytes. Lipids 21:508–514.

[81] el Kebbab, M.H., Cherkauer Maki, M., Labruffe, N., 1995. Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochemistry and Molecular Biology International 35:65–77.

[82] Krueger, R.G., Saneck, L.D., Boechl, J.M., 1976. Tumor-associated antigens in human myeloma. Journal of the National Cancer Institute 56:711–715.

[83] Kersten, S., 2008. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Research 2008:132960.

[84] Haluzik, M.M., Lacinova, Z., Dolinkova, M., Haluzikova, D., Housa, D., Horinek, A., et al., 2006. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147:4517–4524.

[85] Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., et al., 2006. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal of Pharmacology 536:182–191.

[86] Chan, S.M., Sun, R.Q., Zeng, X.Y., Choong, Z.H., Wang, H., Watt, M.J., et al., 2013. Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased ER stress. Diabetes 62:2095–2010.

[87] Hwang, B., Wu, P., Harris, R.A., 2012. Additive effects of clofibrate acid and pyruvate dehydrogenase kinase isozyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. FEBS Journal 279:1883–1893.

[88] Sasaki, Y., Shimada, T., Izuoka, S., Suzuki, W., Makihara, H., Terakoa, R., et al., 2011. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. European Journal of Pharmacology 662:1–8.

[89] Tailleux, A., Wouters, K., Staels, B., 2012. Roles of PPARs in NAFLD: potential therapeutic targets. Biochimica et Biophysica Acta 1821:809–818.

[90] Thomsen, M.S., Christiansen, E.N., Norum, K.R., 1982. Characterization of the stimulatory effect of high-fat diets on peroxisomal beta-oxidation in rat liver. Biochemical Journal 206:195–202.

[91] Ye, J.M., Doyle, P.J., Iglesias, M.A., Watson, D.G., Cooney, G.J., Kraegen, E.W., 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high-fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50:411–417.

[92] Fabbrini, E., Mohammad, B.S., Korenblat, K.M., Magkos, F., McCrea, J., Patterson, B.W., et al., 2010. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 95:2727–2735.

[93] Oosterveer, M.H., Greffhorst, A., van Dijk, T.H., Havinga, R., Staels, B., Kuipers, F., et al., 2009. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. Journal of Biological Chemistry 284:34036–34044.

[94] Chen, X., Matthews, J., Zhou, L., Pelton, P., Liang, Y., Xu, J., et al., 2008. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism 57:1516–1525.

[95] Guerre-Millo, M., Gervois, P., Raspe, E., Madsen, L., Poulain, P., Denudas, B., et al., 2000. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. Journal of Biological Chemistry 275:16638–16642.

[96] Schafer, H.L., Linz, W., Falk, E., Gien, M., Glombik, H., Korn, M., et al., 2012. AVE8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta pharmacologica Sinica 33:82–90.
Enger, S.C., Johnsen, V., Samuelson, A., Løves, E.A., 1977. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease. Acta Medica Scandinavica 201:563–566.

Ferrari, C., Frestzzi, S., Romussi, M., Bertazzoni, A., Testori, G.P., Antonini, S., et al., 1977. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia. Metabolism 26:129–139.

Ferrari, C., Testori, G.P., Bertazzoni, A., Romussi, M., Caldara, R., Frestzzi, S., 1978. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes. Hormone and Metabolic Research — Hormon- und Stoffwechselorschung — Hormones et metabolisme 10:4–6.

Kobayashi, M., Shigeta, Y., Hirata, Y., Omori, Y., Sakamoto, N., Nambu, S., et al., 1988. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11:495–499.

Anderlova, K., Dolezalova, R., Housova, J., Bosanska, L., Haluzikova, D., Belfort, R., Berria, R., Cornell, J., Cusi, K., 2010. Fenofibrate and statins rapidly and synergistically activates the peroxisome proliferator-activated receptor-alpha agonist fenofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 95:829–836.

Perreault, L., Bergman, B.C., Hunerdosse, D.M., Howard, D.J., Eckel, R.H., 2011. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metabolism 60:1107–1114.

Subramanian, S., DeRosa, M.A., Bernal-Mizrachi, C., Lafleff, N., Cade, W.T., Yarasheski, K.E., et al., 2006. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. American Journal of Physiology — Endocrinology and Metabolism 291: E1305–E1317.

Tomkiewicz, C., Muzeau, F., Edgar, A.D., Baruaski, R., Aggerbeck, M., 2004. Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates. Biochemical Pharmacology 67:213–225.

Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., Wahl, W., 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proceedings of the National Academy of Sciences of the United States of America 90:2169–2164.

Kliwer, S.A., Sundseth, S.S., Jones, S.A., Brown, P.J., Wisely, G.B., Koble, C.S., et al., 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proceedings of the National Academy of Sciences of the United States of America 94:4318–4323.

Krey, G., Braissant, O., L’Hortet, F., Kålhoven, E., Perroud, M., Parker, M.G., et al., 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molecular Endocrinology 11:779–791.

Lin, Q., Ruuska, S.E., Shaw, N.S., Dong, D., Ney, N., 1999. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 38:185–190.

Makino, T., Kinoshita, J., Arakawa, S., Ito, K., Ando, Y., Yamoto, T., et al., 1988. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes. Hormone and Metabolic Research — Hormon- und Stoffwechselorschung — Hormones et metabolisme 10:4–6.

Motojima, K., Seto, K., 2003. Fibrates and statins rapidly and synergistically increase pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. Biological and Pharmaceutical Bulletin 26:954–958.

Walters, M.W., Wallace, K.B., 2010. Urea cycle gene expression is suppressed by PFOA treatment in rats. Toxicology Letters 197:46–50.

Edvardsson, U., von Lowenhielm, H.B., Panfilov, O., Nystrom, A.C., Nilsson, F., Dahlbo, B., 2003. Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 3:468–478.

Leondard, J.F., Coursoul, M., Mariet, C., Charbonnier, A., Boitier, E., Duchesne, M., et al., 2006. Proteomic characterization of the effects of clofibrate on protein expression in rat liver. Proteomics 6:1915–1933.

Maxino, T., Kinoshiita, J., Arakawa, S., Ito, K., Ando, Y., Yamato, T., et al., 2009. Comprehensive analysis of hepatic gene and protein expression profiles on phenobarbitol- or clofibrate-induced hepatic hypertrophy in dogs. Journal of Toxicological Sciences 34:647–661.

Shoiki, K., Camego, G., Lanne, B., Halvarsson, T., Landergren, M.R., Oakes, N.D., 2007. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. American Journal of Physiology — Endocrinology and Metabolism 292: E1157–E1165.

Edgar, A.D., Tomkiewicz, C., Costet, P., Legendre, C., Aggerbeck, M., Bouguet, J., et al., 1998. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicology Letters 98:13–23.

Thuill, P., Rafter, I., Stockling, K., Tomkiewicz, C., Norjavaara, E., Aggerbeck, M., et al., 2008. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicology and Applied Pharmacology 231:1–9.
Review

ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with co-factors. Journal of Biological Chemistry 276:21410–21416.

Chakravarty, M.V., Lodhi, I.J., Yin, L., Malapaka, R.R., Xu, H.E., Turk, J., et al., 2009. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138:476–488.

Liu, S., Brown, J.D., Stanya, K.J., Homan, E., Leidl, M., Inouye, K., et al., 2010. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. American Journal of Physiology 319:R282–R291.

Wolfrum, C., Borrmann, C.M., Borchers, T., Spener, F., 2001. Fatty acids and peroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry 40:2484–2500.

Huang, H., Starodub, O., McIntosh, A., Kier, A.B., Schroeder, F., 2002. Liver fatty acid binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. Journal of Biological Chemistry 277:29139–29151.

Hostetter, H.A., McIntosh, A.L., Alsheba, B.P., Storey, S.M., Payne, H.R., Kier, A.B., et al., 2009. L-FABP directly interacts with PPARalpha in cultured primary hepatocytes. Journal of Lipid Research 50:1663–1675.

McIntosh, A.L., Alsheba, B.P., Hostetter, H.A., Huang, H., Davis, J., Lyuksyutova, O.I., et al., 2009. Liver type fatty acid binding protein (L-FABP) gene ablation reduces nuclear ligand distribution and peroxisome proliferator-activated receptor-alpha activity in cultured primary hepatocytes. Archives of Biochemistry and Biophysics 485:160–173.

Wolfson, C., Bormann, C.M., Borchers, T., Spener, F., 2001. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 98:2323–2328.

Kozawa, S., Honda, A., Kajiwara, N., Takemoto, Y., Nagase, T., Nikami, H., et al., 2011. Induction of peroxisomal lipid metabolism in mice fed a high-fat diet. Molecular Medicine Reports 4:1157–1162.

Patsouris, D., Reddy, J.K., Muller, M., Kersten, S., 2006. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147:1508–1516.

Sunny, N.E., Satapati, S., Fu, X., He, T., Mehdibeigi, R., Spring-Robinson, C., et al., 2010. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. American Journal of Physiology — Endocrinology and Metabolism 298:E1226–E1235.

Brady, P.S., Marine, K.A., Brady, L.J., Ramsay, R.R., 1989. Co-ordinate inactivation of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochemical Journal 260:93–100.

Ouali, F., Djourdi, F., Merlet-Benichou, C., Riveau, B., Bastin, J., 2000. Regulation of fatty acid transport protein and mitochondrial and peroxisomal beta-oxidation gene expression by fatty acids in developing cataracts. Pediatric Research 48:691–696.

Duval, C., Thiesen, U., Keshthkar, S., Accart, B., Stienstra, R., Boekschoten, M.V., et al., 2010. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 59:3181–3191.

Gavrilova, O., Haluzik, M., Matsuse, K., Cutson, J.J., Johnson, L., Dietz, K.R., et al., 2003. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry 278:34268–34276.

Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., et al., 2005. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochemical and Biophysical Research Communications 336:215–222.

Badman, M.K., Fissios, P., Kennedy, A.R., Kouskos, G., Flier, J.S., Maratos-Flier, E., 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5:426–437.

Garbrow, J.R., Doherty, J.M., Schugur, R.C., Travers, S., Weber, M.L., Wentz, A.E., et al., 2011. Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet. American Journal of Physiology — Gastrointestinal and Liver Physiology 300:956–967.

Martin, P.G., Guillou, H., Lasserre, F., Dejean, S., Lan, A., Pascussi, J.M., et al., 2007. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 45:767–777.

Ren, B., Thelen, A.P., Peters, J.M., Gonzalez, F.J., Jump, D.B., 1997. Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 272:26827–26832.

Lu, Y., Boekschoten, M.V., Wopereis, S., Muller, M., Kersten, S., 2011. Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiological Genomics 43:1307–1318.

Nilsson, A., Arey, H., Pedersen, J.I., Christiansen, E.N., 1986. The effect of high-fat diets on microsomal lauric acid hydroxylation in rat liver. Biochimica et Biophysica Acta 879:209–214.

Yamazaki, R.K., Shen, T., Schade, G.B., 1987. A diet rich in (n-3) fatty acids increases peroxisomal beta-oxidation activity and lowers plasma triacylglycerols without inhibiting glutathione-dependent detoxication activities in the rat liver. Biochimica et Biophysica Acta 920:62–67.

Jia, Y., Kim, J.Y., Jun, H.J., Kim, S.J., Lee, J.H., Hoang, M.H., et al., 2013. Cyainidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid. Biochimica et Biophysica Acta 1831:698–708.

Jia, Y., Kim, J.Y., Jun, H.J., Kim, S.J., Lee, J.H., Hoang, M.H., et al., 2012. The natural carotenoid astaxanthin, a PPAR-alpha agonist and PPAR-gamma antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes. Molecular Nutrition & Food Research 56:878–888.

Jia, Y., Bhuiyan, M.J., Jun, H.J., Lee, J.H., Hoang, M.H., et al., 2011. Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorganic and Medicinal Chemistry Letters 21:5876–5880.

Rimando, A.M., Nagmani, R., Feller, D.R., Yokoyama, W., 2005. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isomor, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. Journal of Agricultural and Food Chemistry 53:3403–3407.

Shimura, M., Hasumi, A., Minato, T., Hoxono, M., Miura, Y., Mizutani, S., et al., 2005. Isohumulones modulate blood lipid status through the activation of PPAR alpha. Biochimica et Biophysica Acta 1736:51–60.

Mezei, O., Li, Y., Muller, E., Ross-Viola, J.S., Shay, N., 2006. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and —independent mechanisms. Physiological Genomics 26:8–14.

Moya-Camarena, S.Y., Vanden Heuvel, J.P., Blanchard, S.G., Leenstra, L.A., Belury, M.A., 1999. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. Journal of Lipid Research 40:1426–1433.

Rakhshandehroo, M., Hooveld, G., Muller, M., Kersten, S., 2009. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4:e69796.

Duchêne, S., Podechard, N., Lasserre, F., Polizzi, A., Pommier, A., Murzilli, S., et al., 2013. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARalpha. Biochimie 95:556–567.
Willson, T.M., Brown, P.J., Sternbach, D.D., Herken, B.R., 2000. The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 43: 527–550.

Hoekstra, M., Krujit, J.K., Van Eck, M., Van Berkel, T.J., 2003. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. Journal of Biological Chemistry 278:25448–25453.

Mandard, S., Muller, M., Kersten, S., 2004. Peroxisome proliferator-activated receptor alpha target genes. Cellular and Molecular Life Sciences 61: 393–416.

Rakshandehroo, M., Knock, B., Muller, M., Kersten, S., 2010. Peroxisome proliferator-activated receptor alpha target genes. PPAR Research 2010, 425.

Lee, J.H., Giannikopoulos, P., Duncan, S.A., Wang, J., Johansen, C.T., Brown, J.D., et al., 2011. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nature Medicine 17:812–815.

Imagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., et al., 2007. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 5: 415–425.

Lundasen, T., Hunt, M.C., Nilsson, L.M., Sanyal, A., Angelin, B., Alexson, S.E., et al., 2007. PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 360:437–440.

Zandbergen, F., Mandard, S., Escher, P., Tan, N.S., Patsouris, D., Jaktoe, T., et al., 2005. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochemical Journal 392:313–324.

Kim, H.B., Mendez, R., Zheng, Z., Chang, L., Cai, J., Zhang, R., et al., 2014. Liver-enriched transcription factor CREB6 interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology 155:769–782.

Guillaumond, F., Grechce-Cassiau, A., Subramaniam, M., Brangolo, S., Peteri-Brunback, B., Staels, B., et al., 2010. Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver and muscle. Cellular and Molecular Biology 30:3059–3070.

Zhang, H., Chen, Q., Yang, M., Zhu, B., Cui, Y., Xue, Y., et al., 2012. Mouse KLF11 regulates hepatic lipid metabolism. Journal of Hepatology 58:763–770.

Gill, G., Ptashne, M., 1988. Negative effect of the transcriptional activator GAL4. Nature 334:721–724.

Mcmullen, P.D., Bhattacharya, S., Woods, C.G., Sun, B., Yarborough, K., Ross, S.M., et al., 2013. A map of the PPARalpha transcription regulatory network for primary human hepatocytes. Chemico-biological Interactions 209C:14245.

van der Meer, D.L., Degenhardt, T., Vaisanen, S., de Groot, P.J., van Heeringen, S.J., Guillaumond, F., Grechez-Cassiau, A., Subramaniam, M., Brangolo, S., Lundasen, T., Hunt, M.C., Nilsson, L.M., Sanyal, A., Angelin, B., Alexson, S.E., Krammer, J., Digel, M., Ehehalt, F., Steemmel, W., Fullekrug, J., Ehehalt, R., 2011. Overexpression of COX2 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. International Journal of Medical Sciences 8:599–614.

Acute inflammatory response. Nature Medicine 27:25448–25453.

Hsu, M.H., Savas, U., Griffin, K.J., Johnson, E.F., 2001. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. Journal of Biological Chemistry 276:27950–27958.

Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahl, W., et al., 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. Journal of Biological Chemistry 270:19269–19276.

Dongol, B., Shah, Y., Kim, I., Gonzalez, F.J., Hunt, M.C., 2007. The acyl-CoA thioesterase l is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. Journal of Lipid Research 48:1781–1791.

Brandle, R., Kaikaus, R.M., Lysenko, N., Ockner, R.K., Bass, N.M., 1990. Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation. Biochimica et Biophysica Acta 1034:53–61.

Poirier, H., Niot, I., Monnot, M.C., Braissant, O., Meunier-Durmort, C., Hagenbeek, D., Bindesboll, C., et al., 2012. Genome-wide protein-protein interaction network for primary human hepatocytes. Chemico-biological Interactions 200:285–290.

Rampfer, S., Weinhofer, I., Netlik, A., Forss-Petter, S., Brown, P.J., Oplinger, J.A., et al., 2003. Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism 80:398–407.

Leclercq, S., Krzypusz, J., Curvoisier, A., Gondcaille, C., Bonnetain, F., Andre, A., et al., 2008. Effect of dietary polysaturated fatty acids on the expression of peroxisomal ABC transporters. Biochimie 90:1602–1607.

Hunt, M.C., Solaas, K., Kase, B.F., Sartorelli, S.E., 2002. Characterization of an acyl-coA thioesterase that functions as a major regulator of peroxisomal lipid metabolism. Journal of Biological Chemistry 277:1128–1138.

Bardot, O., Aldridge, T.C., Lattrufe, N., Green, S., 1993. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochemical and Biophysical Research Communications 192:37–45.

Marcus, S.L., Miyata, K.S., Zhang, B., Subramani, S., Rachubinski, R.A., Capone, J.P., 1993. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proceedings of the National Academy of Sciences of the United States of America 90:5723–5727.

Nicolis-Frances, V., Gastal, V.K., Abruzzi, E., Osumi, T., Lattrufe, N., 2000. The peroxisome proliferator response element (PPRE) present at positions −681/−669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally
interacts differently with PPARalpha and HNF-4. Biochemical and Biophysical Research Communications 269:347–351.

[194] Shimizu, M., Takeshita, A., Tsukamoto, T., Gonzalez, F.J., Osuni, T., 2004. Tissue-selective, bidirectional regulation of PEX11 alpha and perilipin genes through a common peroxisome proliferator response element. Molecular and Cellular Biology 24:1313–1323.

[195] Brandt, J.M., Dujadi, F., Kelly, D.P., 1998. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 273:23786–23792.

[196] Mascaro, C., Acosta, E., Ortiz, J.A., Marrero, P.F., Hegardt, F.G., Haro, D., 1998. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. Journal of Biological Chemistry 273:8560–8563.

[197] van Vlies, N., Ferdinandusse, S., Turkenburg, M., Wanders, R.J., Vaz, F.M., 2007. PPAR alpha-activation results in enhanced cardiac biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochemistry et Biophysica Acta 1767:1134–1142.

[198] Wen, G., Ringsseis, R., Eder, K., 2010. Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha) via a PPRE located in the first intron. Biochemical Pharmacology 79:768–776.

[199] Gulick, T., Cresci, S., Caira, T., Moore, D.D., Kelly, D.P., 1994. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proceedings of the National Academy of Sciences of the United States of America 91:11012–11016.

[200] Freeman, F.E., 1988. Acyl-CoA dehydrogenases, electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase. Biochemical Society Transactions 16:416–418.

[201] Rodriguez, J.C., Gil-Gomez, G., Hegardt, F.G., Haro, D., 1994. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. Journal of Biological Chemistry 269:18767–18772.

[202] Kroetz, D.L., Youk, P., Costet, P., Bianchi, P., pineau, T., 1998. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. Journal of Biological Chemistry 273:31581–31589.

[203] Muerhoff, A.S., Griffin, K.J., Johnson, E.F., 1992. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. Journal of Biological Chemistry 267:19051–19053.

[204] Wanders, R.J., Komen, J., Kemp, S., 2011. Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS Journal 278:182–194.

[205] Miller, C.W., Ntambi, J.M., 1996. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proceedings of the National Academy of Sciences of the United States of America 93:9443–9448.

[206] Cherkau-Malki, M., Meyer, K., Cao, W.Q., Otsuni, T., 2004. Peroxisome proliferator-activated receptor alpha (PPARalpha) targets genes in mouse liver using cDNA microarray analysis. Gene Expression 9:291–304.

[207] Yu, S., Cao, W.Q., Kashireddy, P., Meyer, K., Jia, Y., Hughes, D.E., et al., 2001. Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver. Journal of Biological Chemistry 276:42485–42491.

[208] Dalen, K.T., Utven, S.M., Ambsen, B.M., Solaas, K., Nebb, H.I., 2006. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. Journal of Lipid Research 47:931–943.

[209] Targell-Adama, P., McElwee, M.J., Ehrenborg, E., Gustafsson, M.C., Palmer, C.N., McLachlan, J., 2005. A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochimica et Biophysica Acta 1728:95–104.

[210] Dalen, K.T., Schoonjans, K., Utven, S.M., Weerdon-Fekjaer, M.S., Bentzen, T.G., Koutnikova, H., et al., 2004. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 53:1243–1252.

[211] Wolins, N.E., Quaynor, B.K., Skinner, J.R., Tsok, A., Croce, M.A., Gropler, M.C., et al., 2006. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 55:3418–3428.

[212] Kaderett, B., Kumar, P., Wang, W.J., Miranda, D., Snapp, E.L., Severina, N., et al., 2008. Evolutionarily conserved gene family important for fat storage. Proceedings of the National Academy of Sciences of the United States of America 105:94–99.

[213] Viswakarma, N., Yu, S., Naik, S., Kashireddy, P., Matsusue, K., Sarkar, J., et al., 2007. Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. Journal of Biological Chemistry 282:18613–18624.

[214] Matsusue, K., Kusakabe, T., Noguchi, T., Takiguchi, S., Suzuki, T., Yamano, S., et al., 2008. Hepatic steatosis in lep-inficient deficient mice is promoted by the PPAR gamma target gene Fsp27. Cell Metabolism 7:302–311.

[215] Costet, P., Legendre, C., More, J., Edgar, A., Gallier, P., Pineau, T., 1998. Peroxisome proliferator-activated receptor alpha isoform deficiency leads to progressive dystypidism with sexually dimorphic obesity and steatois. Journal of Biological Chemistry 273:29577–29585.

[216] Stiensra, S., Mandard, S., Patsouris, D., Maass, C., Kensten, S., Muller, P., 2007. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 148:2753–2763.

[217] Liu, A., Kraus, K.W., Fang, Z.Z., Brocke, C., Qu, A., Gonzalez, F.J., 2014. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARalpha and its relevance to hepatotoxicity. Archives of Toxicology 88:983–996.

[218] Yamazaki, T., Wakabayashi, M., Ikeda, E., Tanaka, S., Sakamoto, T., Matsusue, K., et al., 2012. Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biological and Pharmacetical Bulletin 35:1509–1515.

[219] Kok, T., Wolters, H., Bloks, W.V., Havinga, R., Jansen, P.L., Staelens, B., et al., 2003. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124:160–171.

[220] Gohon, N.S., Anantharayanan, M., Soroka, C.J., Boyer, J.L., 2013. Peroxisome proliferator-activated receptor alpha activates human multilid resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 59:1030–1042.

[221] Hunt, M.C., Yang, Y.Z., Egertson, G., Carneheim, C.M., Gafvels, M., Einarsson, C., et al., 2000. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. Journal of Biological Chemistry 275:28947–28953.

[222] Cinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., et al., 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 7:53–58.

[223] Cinetti, G., Gbaguidi, F.G., Griglio, S., Mattal, Z., Antonucci, M., Poulain, P., et al., 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411–2417.

[224] Lopez, D., McLean, M.P., 2006. Activation of the rat scavenger receptor class B type I gene by PPARalpha. Molecular and Cellular Endocrinology 251:67–77.

[225] Mardones, P., Pilon, A., Boyl, M., Duran, D., Nishimoto, T., Aral, H., et al., 2003. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. Journal of Biological Chemistry 278:7884–7890.
